{
    "pmid": "41357893",
    "title": "Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a ",
    "abstract": "Uncontrolled rheumatoid arthritis (RA) requires increasing the dosage of medications or adding combination therapies, leading to higher costs and increased risks of adverse events. This study aimed to assess the impact of ivarmacitinib, a selective Janus kinase 1 inhibitor, on the needs for adding/escalating medications in patients with moderate-to-severe RA. This was a  Ivarmacitinib 4 mg (7.4%) and 8 mg (5.3%) groups had significantly lower rates of adding/escalating medication compared to the placebo group (22.3%) within W24 (both  Ivarmacitinib significantly reduces the need for adding/escalating medications compared to placebo, thereby potentially decreasing treatment burden. However, the ",
    "disease": "rheumatoid arthritis",
    "clean_text": "ivarmacitinib reduces the need for adding escalating medications in moderate to severe rheumatoid arthritis patients a uncontrolled rheumatoid arthritis ra requires increasing the dosage of medications or adding combination therapies leading to higher costs and increased risks of adverse events this study aimed to assess the impact of ivarmacitinib a selective janus kinase inhibitor on the needs for adding escalating medications in patients with moderate to severe ra this was a ivarmacitinib mg and mg groups had significantly lower rates of adding escalating medication compared to the placebo group within w both ivarmacitinib significantly reduces the need for adding escalating medications compared to placebo thereby potentially decreasing treatment burden however the"
}